Robert W. Tuman
Publications by Year
Research Areas
Pancreatic function and diabetes, Angiogenesis and VEGF in Cancer, Diabetes Treatment and Management, Pharmacogenetics and Drug Metabolism, Estrogen and related hormone effects
Most-Cited Works
- → JNJ-28312141, a novel orally active colony-stimulating factor-1 receptor/FMS-related receptor tyrosine kinase-3 receptor tyrosine kinase inhibitor with potential utility in solid tumors, bone metastases, and acute myeloid leukemia(2009)107 cited
- → R306465 is a novel potent inhibitor of class I histone deacetylases with broad-spectrum antitumoral activity against solid and haematological malignancies(2007)89 cited
- → Comparison and Effects of Natural and Synthetic Glucose Tolerance Factor in Normal and Genetically Diabetic Mice(1978)73 cited
- → Carbohydrate biguanides as potential hypoglycemic agents.(1989)59 cited
- → Studies with an Orally Bioavailable αV Integrin Antagonist in Animal Models of Ocular Vasculopathy: Retinal Neovascularization in Mice and Retinal Vascular Permeability in Diabetic Rats(2007)58 cited
- → New non-steroidal aromatase inhibitors: Focus on R76713(1990)57 cited
- → Metabolic Effects of the Glucose Tolerance Factor (GTF) in Normal and Genetically Diabetic Mice(1977)54 cited
- → Small molecule inhibitors of methionine aminopeptidase type 2 (MetAP-2) fail to inhibit endothelial cell proliferation or formation of microvessels from rat aortic rings in vitro(2004)46 cited
- → A Vascular Endothelial Growth Factor Receptor-2 Kinase Inhibitor Potentiates the Activity of the Conventional Chemotherapeutic Agents Paclitaxel and Doxorubicin in Tumor Xenograft Models(2004)41 cited
- → Aromatase inhibition by R 76713: Experimental and clinical pharmacology(1989)37 cited